Effectiveness of Ivermectin among COVID-19 patients: A Randomized Controlled Trial

  • Muhammad Umar Rawalpindi Medical University
  • Rizwana Shahid Rawalpindi Medical University
  • Muhammad Mujeeb Khan Holy Family Hospital , Rawalpindi Medical University
  • Uzma Hayat Rawalpindi Medical University
  • Ayesha Nadar Holy Family Hospital
  • Sheema Afzal Holy Family Hospital , Rawalpindi Medical University
Keywords: Ivermectin, Randomized Controlled Trial, COVID-19, PCR, Clinical Severity Score.

Abstract

Objectives: To determine the effectiveness of Ivermectin among COVID-19 patients in terms of mortality and biochemical / hematological attributes.

Materials and Methods:  A Randomized Controlled Trial (RCT) was carried out in Department of Infectious Diseases (DID) of Holy Family Hospital Rawalpindi during March 2021 through concurrent parallel study design. Apart from seeking Ethical approval for this research, DID was also licensed from Drug Regulatory Authority of Pakistan (DRAP) for this trial. Total 90 PCR positive COVID-19 patients were enrolled in this study via 1:1 randomization in experimental and control group without blinding. The control group received Standard of Care (SOC) starting from day 1 while experimental group was given SOC along with Ivermectin (200µg/kg) for 5 days. Study participants were assessed on day 0, 4, 7 and 10 for general symptoms through physical examination, blood oxygen saturation and diverse hematological and biochemical indicators in addition to adverse events. Data analysis was done by means of SPSS version 25.0. and Microsoft Excel 2010. Mean ± SD for age, length of hospital stay and time to PCR negativity were calculated. Independent sample t-test was applied to determine the mean difference in age, duration of hospital stay, time to PCR negativity, SpO2, oxygen supply, serum Hemoglobin, TLC, platelet count, Clinical Severity Score (CSS), urea and creatinine levels of both groups. The difference in secondary outcome (expiry / discharge) of both groups was compared by means of chi-square test. P-value ≤ 0.05 was considered significant. 95% Confidence Interval was also computed. Relative Risk (RR) was also measured to verify the effectiveness of Ivermectin in COVID patients

Results: Males constituted the majority (56.7%) of our study participants. Statistically insignificant difference in mean age (P = 0.42) and mean length of hospital stay (P= 0.32) between experimental and control group subjects was observed. Mean time to PCR negativity was reported to be significantly less (P= 0.002) in experimental group. Significant improvement was seen in PCR negativity (P<0.05), mean Clinical Severity Score (CSS) (P0.02), mean hemoglobin level (P=0.03) and mean platelet count (P=0.03). Difference in health outcome of both groups was determined to be statistically insignificant (P<0.2, 95% CI (-0.20 – 0.12)). Relative Risk of 0.8 proved the protective effect of Ivermectin in COVID.

Conclusion: Ivermectin was quite effective in reducing mortality and improving the health outcome in COVID-19 patients.

Author Biographies

Muhammad Umar, Rawalpindi Medical University

Vice Chancellor RMU

Muhammad Mujeeb Khan, Holy Family Hospital , Rawalpindi Medical University

Associate Professor of Infectious Diseases, Holy Family Hospital, affilaited with Rawalpindi Medical University 

Uzma Hayat, Rawalpindi Medical University

Senior Demonstrator Community Medicine, Rawalpindi Medical University

Ayesha Nadar, Holy Family Hospital

Medical Officer Infectious Diseases Department, Holy Family Hospital

Sheema Afzal, Holy Family Hospital , Rawalpindi Medical University

Medical Officer Infectious Diseases Department, Holy Family Hospital

References

2. Douglas M, Katikireddi SV, Taulbut M, McKee M, McCartney G. Mitigating the wider health effects of COVID-19 pandemic response. BMJ 2020; 369: m1557. doi: https://doi.org/10.1136/bmj.m1557.
3. Jeon J, Baruah G, Sarabadani S, Palanica A. Identification of risk factors and symptoms of COVID-19: Analysis of biomedical literature and social media data. J Med Internet Res 2020; 22(10):e20509. doi: 10.2196/20509.
4. Kontis V, Bennett JE, Rashid T, Parks RM, Pearson-Stuttard J, Guillot M, et al. Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. Nature Medicine 2020; 26: 1919-1928.
http:\\doi.org\10.1038\s41591-020-1112-0. /10.1038/s41591-020-1112-0
5. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines. Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1-9. doi:10.12932/AP-200220-0772.
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19) A Review. JAMA 2020; 323(18): 1824-1836. http://jamanetwork.com/.
7. NIH. COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/whats-new/. Accessed on 5th June 2021.
8. NIH plans research on “Long COVID”. https://covid19.nih.gov/. Accessed on 5th June 2021.
9. Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med 2020; doi: 10.1038/d41591-020-00019-9.
10. Adams K. 3 common drugs being tested to treat early-stage COVID-19. Becker’s Hospital Review. https://www.beckershospitalreview.com/pharmacy/3-common-drugs-being-tested-to-treat-early-stage-covid-19.html.
11. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment options for COVID-19: A Review. Front Med (Lousanne) 2020; 7: 4. doi: 10.3389/fmed.2020.00480.
12. Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19.
13. Yagisawa M, Foster PJ, Hanaki H, Omura S. Global trends in clinical studies of Ivermectin in COVID-19. The Japanese Journal of Antibiotics 2021; 74(1): 44-95.
14. Government of Pakistan. Ministry of National Health Services, Regulation & Coordination. Clinical Management Guidelines for COVID-19 Infections. 2 April 2020. https://covid.gov.pk/guidelines/pdf/20200402%20Clinical%20Management%20Guidelines%20for%20COVID-19%20infections_1201.pdf.
15. COVID-19 Statistics. https://www.google.com/search?q=covid+deaths+globally&rlz=1C1GCEA_enPK861PK861&oq=covid+deaths+globally+&aqs=chrome..69i57j0l9.6469j0j7&sourceid=chrome&ie=UTF-8.
16. Khullar D, Bond AM, Schpero WL, COVID-19 and the financial health of US hospitals. JAMA 2020; 323: 2127-8.
17. Rasheed R, Rizwan A, Javed H, Sharif F, Zaidi A. Socio-economic and environmental impacts of COVID-19 pandemic in Pakistan – an integrated analysis. Environ Sci Pollut Res Int 2021; 28(16):19926-19943. doi: 10.1007/s11356-020-12070-7.
18. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob 2020. 19(1): 23. https://doi.org/10.1186/s12941-020-00368-w.
19. Hashim HA, Maulood MF, Rasheed, AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. Preprint. medRxiv. 2020; https:// doi. org/ 10. 1101/2020. 10. 26. 20219 345.
20. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermection in COVID Nineteen study. Chest 2021; 159(1):85-92. doi: 10.1016/j.chest.2020.10.009.
21. Elgazzar A, Hany B, Abo Youssef S, Hafez M, Moussa H. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Preprint. Research Square 2020; https://doi.org/ 10. 21203/ rs.3. rs100 956/ v1.
22. Behera P, Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS ONE 2021; 16(2): e0247163. https://doi.org/10.1371/journal.pone.0247163.
23. Chen C, Lin Y, Chen T, Tseng T, Wong H, Kuo C, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS ONE 2020; 15(12): e0242763. https://doi.org/10.1371/journal.pone.0242763.
24. Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, et al. Ivermectin shows clinical benefits in mild to moderate COVID-19: A randomized controlled double-blind, dose-response study in Lagos. QJM: An Int J Med 2021; 00(0): 1-9. https://doi.org/10.1093/qjmed/hcab035.
25. Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof- of-concept randomized trial. EClinicalMedicine 2021; 37: 100959. DOI:https://doi.org/10.1016/j.eclinm.2021.100959.
26. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. 31st March 2021. https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials.
27. Okumus N, Demirturk N, Cetinkaya RA, Guner R, Avci IY, Orhan S, et al. Evaluation of effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infectious Diseases 2021; 21: 411. https://doi.org/10.1186/s12879-021-06104-9.
28. Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double blind, placebo-controlled trial. BMC Infect Dis 2021; 635. https://doi.org/10.1186/s12879-021-06348-5.
Published
2022-06-30
How to Cite
1.
Umar M, Shahid R, Khan M, Hayat U, Nadar A, Afzal S. Effectiveness of Ivermectin among COVID-19 patients: A Randomized Controlled Trial. JRMC [Internet]. 30Jun.2022 [cited 24Sep.2022];26(2):236-41. Available from: http://www.journalrmc.com/index.php/JRMC/article/view/1802
Section
Articles

Most read articles by the same author(s)